These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29705128)

  • 1. Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN-λ4.
    Bhushan A; Chinnaswamy S
    Gene; 2018 Jul; 664():168-180. PubMed ID: 29705128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
    Bhushan A; Ghosh S; Bhattacharjee S; Chinnaswamy S
    J Interferon Cytokine Res; 2017 Aug; 37(8):369-382. PubMed ID: 28727946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.
    Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Grønbæk H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J;
    Nat Genet; 2017 May; 49(5):795-800. PubMed ID: 28394349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional genetic variants of the IFN-λ3 (IL28B) gene and transcription factor interactions on its promoter.
    Roy S; Guha Roy D; Bhushan A; Bharatiya S; Chinnaswamy S
    Cytokine; 2021 Jun; 142():155491. PubMed ID: 33725487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
    Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
    BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender-dependent multiple cross-phenotype association of interferon lambda genetic variants with peripheral blood profiles in healthy individuals.
    Roy DG; Singh L; Chaturvedi HK; Chinnaswamy S
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2292. PubMed ID: 37795763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
    Lu YF; Goldstein DB; Urban TJ; Bradrick SS
    Virology; 2015 Feb; 476():334-340. PubMed ID: 25577150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection.
    Waldenström J; Kåberg M; Alanko Blomé M; Widell A; Björkman P; Nilsson S; Hammarberg A; Weiland O; Nyström K; Lagging M
    Scand J Gastroenterol; 2021 Jul; 56(7):855-861. PubMed ID: 34034600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.
    Galmozzi E; Facchetti F; Grossi G; Loglio A; Viganò M; Lunghi G; Colombo M; Lampertico P
    Liver Int; 2018 Mar; 38(3):417-423. PubMed ID: 28732143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-λ4 is associated with increased risk and earlier occurrence of several common infections in African children.
    Prokunina-Olsson L; Morrison RD; Obajemu A; Mahamar A; Kim S; Attaher O; Florez-Vargas O; Sidibe Y; Onabajo OO; Hutchinson AA; Manning M; Kwan J; Brand N; Dicko A; Fried M; Albert PS; Mbulaiteye SM; Duffy PE
    Genes Immun; 2021 May; 22(1):44-55. PubMed ID: 33850301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.
    Grzegorzewska AE
    Curr Med Chem; 2019; 26(25):4832-4851. PubMed ID: 30027841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.
    Riva E; Scagnolari C; Turriziani O; Antonelli G
    Clin Microbiol Infect; 2014 Dec; 20(12):1237-45. PubMed ID: 25273834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-λ4: the paradoxical new member of the interferon lambda family.
    O'Brien TR; Prokunina-Olsson L; Donnelly RP
    J Interferon Cytokine Res; 2014 Nov; 34(11):829-38. PubMed ID: 24786669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of the Human Interferon Lambda Region.
    Prokunina-Olsson L
    J Interferon Cytokine Res; 2019 Oct; 39(10):599-608. PubMed ID: 31070498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus.
    Waldenström J; Hellstrand K; Westin J; Nilsson S; Christensen P; Färkkilä M; Mørch K; Langeland N; Norkrans G; Lagging M
    Scand J Gastroenterol; 2021 Jul; 56(7):849-854. PubMed ID: 34078234
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Baker FS; Wang J; Florez-Vargas O; Brand NR; Ogwang MD; Kerchan P; Reynolds SJ; Tenge CN; Were PA; Kuremu RT; Wekesa WN; Masalu N; Kawira E; Kinyera T; Otim I; Legason ID; Nabalende H; Chagaluka G; Mutalima N; Borgstein E; Liomba GN; Kamiza S; Mkandawire N; Mitambo C; Molyneux EM; Newton R; Prokunina-Olsson L; Mbulaiteye SM
    J Interferon Cytokine Res; 2023 Sep; 43(9):394-402. PubMed ID: 37366802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
    Sakr AA; Ahmed AE; Abd El-Maksoud MDE; Gamal A; El-Garem H; Ahmed OM
    Infect Genet Evol; 2020 Dec; 86():104606. PubMed ID: 33127459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.